Literature DB >> 9317164

Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens.

E Okada1, S Sasaki, N Ishii, I Aoki, T Yasuda, K Nishioka, J Fukushima, J Miyazaki, B Wahren, K Okuda.   

Abstract

A DNA vaccine constructed with the CMV promoter conjugated to env gp160 and rev genes has been shown to induce an effective Th1-type immune response when inoculated via an intramuscular route. In the present study, we obtained high levels of both humoral and cell-mediated immune activity by intranasal administration of this DNA vaccine. The production of mucosal IgA Ab in feces and vaginal fluid was stimulated significantly by intranasal DNA administration. This route of administration resulted in a significant level of HIV-1-neutralizing Abs in feces and serum. Cytokine assays revealed that intranasal administration of this DNA vaccine induces a Th2-type immune response. Interestingly, cationic liposomes greatly enhanced these activities. Abs against HIV-1 were present for at least 10 mo. Coadministration of the DNA vaccine with IL-12- and granulocyte/macrophage-CSF-expressing plasmids induced high levels of HIV-specific CTLs and an increase in delayed type hypersensitivity when administered by the intranasal route. These results clearly demonstrate that intranasal administration of this DNA vaccine with liposomes, together with IL-12- and/or granulocyte/macrophage-CSF-expressing plasmids, induces a strong level of anti-HIV-1 immune response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9317164

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  54 in total

Review 1.  Interleukin 12 and innate molecules for enhanced mucosal immunity.

Authors:  P N Boyaka; J W Lillard; J McGhee
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice.

Authors:  S Kawabata; Y Terao; T Fujiwara; I Nakagawa; S Hamada
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

Review 3.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

Review 4.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols.

Authors:  T Yoshida; K Okuda; K Q Xin; K Tadokoro; J Fukushima; S Toda; E Hagiwara; K Hamajima; T Koshino; T Saito
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

6.  Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes.

Authors:  Marilyn E Ferrari; Denis Rusalov; Joel Enas; Carl J Wheeler
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

Review 7.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

8.  Protective antiviral immune responses to pseudorabies virus induced by DNA vaccination using dimethyldioctadecylammonium bromide as an adjuvant.

Authors:  Eugene M A van Rooij; Harrie L Glansbeek; Luuk A T Hilgers; Eddie G te Lintelo; Yolanda E de Visser; Wim J A Boersma; Bart L Haagmans; Andre T J Bianchi
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Authors:  Kenji Someya; Ke-Qin Xin; Kazuhiro Matsuo; Kenji Okuda; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.